MannKind Corporation (NASDAQ:MNKD), VP Juergen Martens sold 76,899 shares of the company’s stock on the open market in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $7.50, for a total transaction of $576,742.50. Following the sale, the vice president now directly owns 139,024 shares of the company’s stock, valued at approximately $1,042,680. MannKind Corporation (NASDAQ:MNKD), weekly performance is 11.98%. On last trading day company shares ended up $7.76. Analysts mean target price for the company is $8.07. MannKind Corporation (NASDAQ:MNKD), distance from 50-day simple moving average (SMA50) is 24.55%.
Gilead Sciences, Inc. (NASDAQ:GILD), announced results from a placebo-controlled, Phase 2a challenge study in healthy adult patients intranasally infected with respiratory syncytial virus (RSV). The study of GS-5806, an investigational oral RSV fusion inhibitor, achieved its primary and secondary endpoints of lower viral load (the amount of virus detected in the nasal wash), improvements in total mucus weight (the amount of mucus produced by the nose) and also symptom diary score compared to placebo. Detailed results from this study (Poster #1008) will be presented during a poster discussion session at the American Thoracic Society 2014 International Conference in San Diego. Gilead Sciences, Inc. (NASDAQ:GILD), advanced 1.33% in last trading session and ended the day on $82.90. GILD, Gross Margin is 77.80% and its return on assets is 19.10%. Gilead Sciences, Inc. (NASDAQ:GILD), quarterly performance is 0.38%.
On May 14, 2014, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), announced that clinical data on Iclusig (ponatinib) and AP26113, its investigational oral inhibitor of anaplastic lymphoma kinase (ALK), will be presented at the Annual Meeting of the American Society of Clinical Oncology being held in Chicago, May 30 to June 3, 2014. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), shares moved down 0.16% in last trading session and was closed at $6.34, while trading in range of $6.27 – 6.50. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), year to date (YTD) performance is -7.04%.
Shares of Cell Therapeutics Inc (NASDAQ:CTIC), gains over 5.50% in opening session on Thursday after an analyst at Ladenburg started coverage on the stock with a Buy rating and set a price target of $6, representing a 120% gain from yesterday’s closing. Cell Therapeutics Inc (NASDAQ:CTIC), ended the last trading day at $2.87. Company weekly volatility is calculated as 6.50% and price to cash ratio as 8.50. Cell Therapeutics Inc (NASDAQ:CTIC), showed a positive weekly performance of 7.09%.
An investor, who currently holds shares of Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), filed a lawsuit in effort to halt the takeover of Chelsea Therapeutics International Ltd. by H. Lundbeck A/S for a value of up to $7.94 per share. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), weekly performance is -0.91%. On last trading day company shares ended up $6.54. Analysts mean target price for the company is $9.50. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), distance from 50-day simple moving average (SMA50) is 17.07%.